Frontlight ResearchEarly access
Taking people in NorwayPhase 1
Melflufen before surgery for recurrent glioblastoma, tested in brain tumor tissue
Tests how melflufen reaches tumor tissue in adults having surgery for recurrent glioblastoma.
Key facts
- Who runs it
- Oncopeptides AB
- Where
- Oslo, NorwaySee the site
- Trial code
- Registry title
- A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Started
- 17 Jun 2026
- Expected to end
- 30 Jul 2027
- Type of study
- Interventional
- Record updated
- 15 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a glioblastoma that has come back and who are already scheduled for surgery. It studies how a single dose of melflufen reaches the tumour tissue.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Recurrent (returning) glioblastoma, with surgery already planned
Where in Norway
- Oslo Universitetssykehus HFOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Melflufen before surgery for recurrent glioblastoma, tested in brain tumor tissueGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 15 May 2026